Beyond Science: Why Better Drugs Are Only Half the Solution for Alzheimer’s

The development of Lecanemab and Donanemab marks a historic turning point in slowing cognitive decline, but scientific breakthroughs alone are insufficient. Future progress depends on integrating blood-based biomarkers for earlier diagnosis and securing the political will to make these expensive treatments accessible to the public.